Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Individual mapping of innate immune cell activation is a candidate marker of patient-specific trajectories of disability worsening in Multiple Sclerosis.

Bodini B, Poirion E, Tonietto M, Benoit C, Palladino R, Maillart E, Portera E, Battaglini M, Bera G, Kuhnast B, Louapre C, Bottlaender M, Stankoff B.

J Nucl Med. 2020 Jan 31. pii: jnumed.119.231340. doi: 10.2967/jnumed.119.231340. [Epub ahead of print]

PMID:
32005777
2.

Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB.

Auvity S, Tonietto M, Caillé F, Bodini B, Bottlaender M, Tournier N, Kuhnast B, Stankoff B.

Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):490-501. doi: 10.1007/s00259-019-04516-z. Epub 2019 Nov 4.

PMID:
31686177
3.

Predicting PET-derived demyelination from multimodal MRI using sketcher-refiner adversarial training for multiple sclerosis.

Wei W, Poirion E, Bodini B, Durrleman S, Ayache N, Stankoff B, Colliot O.

Med Image Anal. 2019 Dec;58:101546. doi: 10.1016/j.media.2019.101546. Epub 2019 Aug 24.

PMID:
31499318
4.

Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.

Vukusic S, Rollot F, Casey R, Pique J, Marignier R, Mathey G, Edan G, Brassat D, Ruet A, De Sèze J, Maillart E, Zéphir H, Labauge P, Derache N, Lebrun-Frenay C, Moreau T, Wiertlewski S, Berger E, Moisset X, Rico-Lamy A, Stankoff B, Bensa C, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Vaillant M, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Tourbah A, Guennoc AM, Hankiewicz K, Patry I, Nifle C, Maubeuge N, Labeyrie C, Vermersch P, Laplaud DA; OFSEP Investigators.

JAMA Neurol. 2019 Sep 3. doi: 10.1001/jamaneurol.2019.2670. [Epub ahead of print]

PMID:
31479149
5.

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.

Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y; SFSEP and OFSEP groups.

Neurology. 2019 Aug 13;93(7):e635-e646. doi: 10.1212/WNL.0000000000007938. Epub 2019 Jul 12.

6.

Severe transient myopathy in a patient with progressive multiple sclerosis and high-dose biotin.

Maillart E, Mochel F, Acquaviva C, Maisonobe T, Stankoff B.

Neurology. 2019 May 28;92(22):1060-1062. doi: 10.1212/WNL.0000000000007576. Epub 2019 Apr 26. No abstract available.

PMID:
31028130
7.

Dynamic 11C-PiB PET Shows Cerebrospinal Fluid Flow Alterations in Alzheimer Disease and Multiple Sclerosis.

Schubert JJ, Veronese M, Marchitelli L, Bodini B, Tonietto M, Stankoff B, Brooks DJ, Bertoldo A, Edison P, Turkheimer FE.

J Nucl Med. 2019 Oct;60(10):1452-1460. doi: 10.2967/jnumed.118.223834. Epub 2019 Mar 8.

8.

Fluid-attenuated inversion recovery MRI synthesis from multisequence MRI using three-dimensional fully convolutional networks for multiple sclerosis.

Wei W, Poirion E, Bodini B, Durrleman S, Colliot O, Stankoff B, Ayache N.

J Med Imaging (Bellingham). 2019 Jan;6(1):014005. doi: 10.1117/1.JMI.6.1.014005. Epub 2019 Feb 19.

9.

PET is necessary to make the next step forward in understanding MS pathophysiology - Yes.

Bodini B, Stankoff B.

Mult Scler. 2019 Jul;25(8):1086-1087. doi: 10.1177/1352458519828298. Epub 2019 Feb 27. No abstract available.

PMID:
30810071
10.

Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.

Vukusic S, Casey R, Rollot F, Brochet B, Pelletier J, Laplaud DA, De Sèze J, Cotton F, Moreau T, Stankoff B, Fontaine B, Guillemin F, Debouverie M, Clanet M.

Mult Scler. 2020 Jan;26(1):118-122. doi: 10.1177/1352458518815602. Epub 2018 Dec 13.

PMID:
30541380
11.

Ultrahigh field imaging of myelin disease models: Toward specific markers of myelin integrity?

Petiet A, Adanyeguh I, Aigrot MS, Poirion E, Nait-Oumesmar B, Santin M, Stankoff B.

J Comp Neurol. 2019 Sep 1;527(13):2179-2189. doi: 10.1002/cne.24598. Epub 2019 Jan 4. Review.

PMID:
30520034
12.

Is it time to conduct phase 3 clinical trials of sex hormones in MS - Commentary.

Dubessy AL, Stankoff B.

Mult Scler. 2018 Oct;24(11):1417-1418. doi: 10.1177/1352458518786071. Epub 2018 Jul 30. No abstract available.

PMID:
30058471
13.

Exploring the heterogeneity of MS lesions using positron emission tomography: a reappraisal of their contribution to disability.

Stankoff B, Poirion E, Tonietto M, Bodini B.

Brain Pathol. 2018 Sep;28(5):723-734. doi: 10.1111/bpa.12641. Review.

PMID:
30020560
14.

Can we use regional grey matter atrophy sequence to stage neurodegeneration in multiple sclerosis?

Stankoff B, Louapre C.

Brain. 2018 Jun 1;141(6):1580-1583. doi: 10.1093/brain/awy114. No abstract available.

PMID:
29800475
15.

Are we missing patients with biotinidase deficiency in France?

Deschamps R, Stankoff B, Vignal C, Benoist JF, Wolf B, Gout O.

Rev Neurol (Paris). 2018 May;174(5):273-274. doi: 10.1016/j.neurol.2017.11.007. No abstract available.

PMID:
29778138
16.

Efficacy of rituximab in refractory RRMS.

Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, Carra-Dalliere C, Labauge P, Mathey G, Debouverie M, Papeix C, Maillart E, Lubetzki C, Bensa C, Gout O, Giannesini C, Stankoff B, Ciron J, Brassat D, Pelletier J, Rico Lamy A, Audoin B.

Mult Scler. 2019 May;25(6):828-836. doi: 10.1177/1352458518772748. Epub 2018 May 3.

PMID:
29722639
17.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
18.

Generalization of endothelial modelling of TSPO PET imaging: Considerations on tracer affinities.

Rizzo G, Veronese M, Tonietto M, Bodini B, Stankoff B, Wimberley C, Lavisse S, Bottlaender M, Bloomfield PS, Howes O, Zanotti-Fregonara P, Turkheimer FE, Bertoldo A.

J Cereb Blood Flow Metab. 2019 May;39(5):874-885. doi: 10.1177/0271678X17742004. Epub 2017 Nov 14.

PMID:
29135382
19.

Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? Comments. Anti-JCV antibody index in multiple sclerosis care.

Stankoff B.

Rev Neurol (Paris). 2017 Dec;173(10):616-618. doi: 10.1016/j.neurol.2017.05.015. Epub 2017 Nov 8. No abstract available.

PMID:
29128153
20.

Impact of Endothelial 18-kDa Translocator Protein on the Quantification of 18F-DPA-714.

Wimberley C, Lavisse S, Brulon V, Peyronneau MA, Leroy C, Bodini B, Remy P, Stankoff B, Buvat I, Bottlaender M.

J Nucl Med. 2018 Feb;59(2):307-314. doi: 10.2967/jnumed.117.195396. Epub 2017 Aug 3.

21.

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.

Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Sèze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, Lubetzki C, Papeix C.

Neurol Neuroimmunol Neuroinflamm. 2017 Apr 14;4(3):e346. doi: 10.1212/NXI.0000000000000346. eCollection 2017 May.

22.

Multimodal partial volume correction: Application to [11C]PIB PET/MRI myelin imaging in multiple sclerosis.

Grecchi E, Veronese M, Bodini B, García-Lorenzo D, Battaglini M, Stankoff B, Turkheimer FE.

J Cereb Blood Flow Metab. 2017 Dec;37(12):3803-3817. doi: 10.1177/0271678X17712183. Epub 2017 Jun 1. Erratum in: J Cereb Blood Flow Metab. 2018 Jan 1;38(6):1120. J Cereb Blood Flow Metab. 2018 Jan 1;38(6):119.

23.

Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.

Bodini B, Branzoli F, Poirion E, García-Lorenzo D, Didier M, Maillart E, Socha J, Bera G, Lubetzki C, Ronen I, Lehericy S, Stankoff B.

Mult Scler. 2018 Mar;24(3):313-321. doi: 10.1177/1352458517698249. Epub 2017 Apr 10.

PMID:
28394203
24.

Imaging markers of multiple sclerosis prognosis.

Louapre C, Bodini B, Lubetzki C, Freeman L, Stankoff B.

Curr Opin Neurol. 2017 Jun;30(3):231-236. doi: 10.1097/WCO.0000000000000456. Review.

PMID:
28362719
25.

Adaptive human immunity drives remyelination in a mouse model of demyelination.

El Behi M, Sanson C, Bachelin C, Guillot-Noël L, Fransson J, Stankoff B, Maillart E, Sarrazin N, Guillemot V, Abdi H, Cournu-Rebeix I, Fontaine B, Zujovic V.

Brain. 2017 Apr 1;140(4):967-980. doi: 10.1093/brain/awx008.

26.

Validation of an automatic reference region extraction for the quantification of [18F]DPA-714 in dynamic brain PET studies.

García-Lorenzo D, Lavisse S, Leroy C, Wimberley C, Bodini B, Remy P, Veronese M, Turkheimer F, Stankoff B, Bottlaender M.

J Cereb Blood Flow Metab. 2018 Feb;38(2):333-346. doi: 10.1177/0271678X17692599. Epub 2017 Feb 9.

27.

Imaging Central Nervous System Demyelination and Remyelination by Positron-Emission Tomography.

Bodini B, Stankoff B.

Brain Plast. 2016 Dec 21;2(1):93-98. doi: 10.3233/BPL-160042. Review.

28.

Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP).

Mult Scler. 2017 Sep;23(10):1377-1384. doi: 10.1177/1352458516678474. Epub 2016 Nov 25.

PMID:
27885065
29.

Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort.

Papeix C, Vukusic S, Casey R, Debard N, Stankoff B, Mrejen S, Uhry Z, Van Ganse E, Castot A, Clanet M, Lubetzki C, Confavreux C; TYSEDMUS and OFSEP Group.

Neurol Neuroimmunol Neuroinflamm. 2016 Oct 28;3(6):e297. eCollection 2016 Dec.

31.

Cholinergic Changes in Aging and Alzheimer Disease: An [18F]-F-A-85380 Exploratory PET Study.

Lagarde J, Sarazin M, Chauviré V, Stankoff B, Kas A, Lacomblez L, Peyronneau MA, Bottlaender M.

Alzheimer Dis Assoc Disord. 2017 Jan-Mar;31(1):8-12. doi: 10.1097/WAD.0000000000000163.

PMID:
27680780
32.

Benzothiazole and stilbene derivatives as promising positron emission tomography myelin radiotracers for multiple sclerosis.

Bodini B, Veronese M, Turkheimer F, Stankoff B.

Ann Neurol. 2016 Jul;80(1):166-7. doi: 10.1002/ana.24667. Epub 2016 May 9. No abstract available.

PMID:
27098444
33.

Recent achievements in stem cell-mediated myelin repair.

Jadasz JJ, Lubetzki C, Zalc B, Stankoff B, Hartung HP, Küry P.

Curr Opin Neurol. 2016 Jun;29(3):205-12. doi: 10.1097/WCO.0000000000000323. Review.

PMID:
27035898
34.

Repair strategies for multiple sclerosis: challenges, achievements and perspectives.

Stankoff B, Jadasz JJ, Hartung HP, Küry P, Zalc B, Lubetzki C.

Curr Opin Neurol. 2016 Jun;29(3):286-92. doi: 10.1097/WCO.0000000000000325. Review.

PMID:
27035897
35.

Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis.

Bodini B, Veronese M, García-Lorenzo D, Battaglini M, Poirion E, Chardain A, Freeman L, Louapre C, Tchikviladze M, Papeix C, Dollé F, Zalc B, Lubetzki C, Bottlaender M, Turkheimer F, Stankoff B.

Ann Neurol. 2016 May;79(5):726-738. doi: 10.1002/ana.24620.

36.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.

Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

37.

The neuronal component of gray matter damage in multiple sclerosis: A [(11) C]flumazenil positron emission tomography study.

Freeman L, Garcia-Lorenzo D, Bottin L, Leroy C, Louapre C, Bodini B, Papeix C, Assouad R, Granger B, Tourbah A, Dollé F, Lubetzki C, Bottlaender M, Stankoff B.

Ann Neurol. 2015 Oct;78(4):554-67. doi: 10.1002/ana.24468. Epub 2015 Aug 21.

PMID:
26292991
38.

Biotinidase deficiency mimicking neuromyelitis optica: Initially exhibiting symptoms in adulthood.

Bottin L, Prud'hon S, Guey S, Giannesini C, Wolf B, Pindolia K, Stankoff B.

Mult Scler. 2015 Oct;21(12):1604-7. doi: 10.1177/1352458515596457. Epub 2015 Jul 22.

PMID:
26203071
39.

Quantification of [(11)C]PIB PET for imaging myelin in the human brain: a test-retest reproducibility study in high-resolution research tomography.

Veronese M, Bodini B, García-Lorenzo D, Battaglini M, Bongarzone S, Comtat C, Bottlaender M, Stankoff B, Turkheimer FE.

J Cereb Blood Flow Metab. 2015 Nov;35(11):1771-82. doi: 10.1038/jcbfm.2015.120. Epub 2015 Jun 10.

40.

Optimized Quantification of Translocator Protein Radioligand ¹⁸F-DPA-714 Uptake in the Brain of Genotyped Healthy Volunteers.

Lavisse S, García-Lorenzo D, Peyronneau MA, Bodini B, Thiriez C, Kuhnast B, Comtat C, Remy P, Stankoff B, Bottlaender M.

J Nucl Med. 2015 Jul;56(7):1048-54. doi: 10.2967/jnumed.115.156083. Epub 2015 May 29.

41.

Advanced imaging tools to investigate multiple sclerosis pathology.

Bodini B, Louapre C, Stankoff B.

Presse Med. 2015 Apr;44(4 Pt 2):e159-67. doi: 10.1016/j.lpm.2015.02.011. Epub 2015 Mar 26. Review.

PMID:
25818312
42.

Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy.

Gasnault J, de Goër de Herve MG, Michot JM, Hendel-Chavez H, Seta V, Mazet AA, Croughs T, Stankoff B, Bourhis JH, Lambotte O, Delfraissy JF, Taoufik Y.

Open Forum Infect Dis. 2014 Aug 26;1(2):ofu074. doi: 10.1093/ofid/ofu074. eCollection 2014 Sep.

43.

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.

Antoniol C, Stankoff B.

Front Immunol. 2015 Jan 5;5:668. doi: 10.3389/fimmu.2014.00668. eCollection 2014. Review.

44.

Biotherapies in multiple sclerosis: a step toward remyelination and neuroprotection?

Dubessy AL, Zujovic V, Papeix C, Stankoff B.

Rev Neurol (Paris). 2014 Dec;170(12):770-8. doi: 10.1016/j.neurol.2014.10.004. Epub 2014 Nov 6. Review.

PMID:
25459127
45.

Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.

Assouad R, Louapre C, Tourbah A, Papeix C, Galanaud D, Lubetzki C, Stankoff B.

Clin Neurol Neurosurg. 2014 Nov;126:55-63. doi: 10.1016/j.clineuro.2014.08.018. Epub 2014 Aug 20.

PMID:
25215443
46.

Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging.

Ciccarelli O, Barkhof F, Bodini B, De Stefano N, Golay X, Nicolay K, Pelletier D, Pouwels PJ, Smith SA, Wheeler-Kingshott CA, Stankoff B, Yousry T, Miller DH.

Lancet Neurol. 2014 Aug;13(8):807-22. doi: 10.1016/S1474-4422(14)70101-2. Epub 2014 Jul 6. Review.

PMID:
25008549
47.

Brain networks disconnection in early multiple sclerosis cognitive deficits: an anatomofunctional study.

Louapre C, Perlbarg V, García-Lorenzo D, Urbanski M, Benali H, Assouad R, Galanaud D, Freeman L, Bodini B, Papeix C, Tourbah A, Lubetzki C, Lehéricy S, Stankoff B.

Hum Brain Mapp. 2014 Sep;35(9):4706-17. doi: 10.1002/hbm.22505. Epub 2014 Mar 31.

PMID:
24687771
48.

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators.

JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240.

PMID:
24566807
49.

Demyelination in multiple sclerosis.

Lubetzki C, Stankoff B.

Handb Clin Neurol. 2014;122:89-99. doi: 10.1016/B978-0-444-52001-2.00004-2. Review.

PMID:
24507514
50.

Clinical relevance of brain volume measures in multiple sclerosis.

De Stefano N, Airas L, Grigoriadis N, Mattle HP, O'Riordan J, Oreja-Guevara C, Sellebjerg F, Stankoff B, Walczak A, Wiendl H, Kieseier BC.

CNS Drugs. 2014 Feb;28(2):147-56. doi: 10.1007/s40263-014-0140-z. Review.

PMID:
24446248

Supplemental Content

Loading ...
Support Center